Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes
Open Access
- 1 June 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 27 (6) , 1687-1694
- https://doi.org/10.1002/hep.510270630
Abstract
Ribavirin, a guanosine analog, used in combination with interferon α (IFN-α) in the treatment of chronic hepatitis induced by hepatitis C virus (HCV) infection, has been shown to improve liver histology and to decrease transaminases even when administered alone. We analyzed the direct effects of ribavirin on the liver by using primary cultures of human and rat hepatocytes. Between 10 to 60 μmol/L, ribavirin was found to inhibit both the synthesis and secretion of whole proteins in a time- and dose-dependent fashion. Such an effect was confirmed by the measurement of albumin and haptoglobin secretion rates. [3H]-Thymidine incorporation was suppressed both in hepatocyte growth factor-stimulated human hepatocytes and in epidermal growth factor (EGF)-stimulated rat hepatocytes in the presence of ribavirin. The inhibitory effect on DNA synthesis was associated with a delayed progression to S phase of the cell cycle, as determined by flow cytometry and detection of cyclin A and cdc2 which are two proteins expressed during the S phase. The inhibition of DNA synthesis, caused by 50 μmol/L ribavirin, was completely restored by the addition of 80 μmol/L guanosine. These observations demonstrate that ribavirin at concentrations close to those found in plasma of treated patients can directly affect hepatic functions in vitro. Its effects could, however, be reduced in vivo by guanosine salvage supply.Keywords
Funding Information
- ICN Pharmaceuticals Inc and INSERM
This publication has 32 references indexed in Scilit:
- Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centersJournal of Hepatology, 1997
- A Practical Guide to the Use of Interferons in the Management of Hepatitis Virus InfectionsDrugs, 1997
- Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis CGastroenterology, 1996
- Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled studyJournal of Hepatology, 1996
- Prolonged therapy of chronic hepatitis C with ribavirinJournal of Viral Hepatitis, 1996
- Combined treatment with interferon alpha‐2b and ribavirin for chronic hepatitis C in patients with a previous non‐response or non‐sustained response to interferon aloneJournal of Medical Virology, 1995
- Inhibition of immune functions by antiviral drugs.Journal of Clinical Investigation, 1991
- Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenaseBiochemistry, 1988
- Mechanism of Action of 1-β-D-Ribofuranosyl-1,2,4-Triazole-3-Carboxamide (Virazole), A New Broad-Spectrum Antiviral AgentProceedings of the National Academy of Sciences, 1973
- Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamideScience, 1972